Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25850181 | 0.89 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL26036548 | 0.87 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL25834992 | 0.86 | ALDH1A1 (0.46) | NPC1NR1H4RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25856862 | 0.85 | NPC1 (0.49) | NPC1NR1H4RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL26036435 | 0.84 | NPC1 (0.48) | NPC1NR1H4RAB9ASMN1; SMN2SMPD1 | |
| SCHEMBL25836967 | 0.83 | CXCR4 (0.49) | NPC1NR1H4RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24340743 | 0.83 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2ALDH1A1SMPD1 | |
| SCHEMBL25836975 | 0.83 | ALDH1A1 (0.48) | NPC1NR1H4RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24340791 | 0.82 | MTNR1A (0.51) | NPC1NR1H4RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25835003 | 0.82 | NOTUM (0.46) | NPC1NR1H4RAB9AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | NPC1 561/4885NR1H4 296/4885RAB9A 1179/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | NPC1 3878/4885NR1H4 2116/4885RAB9A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.